• multiple myeloma - 2nd line (L2) 1
• myofibroblastic tumors
• neurofibroma
• neutropenia
• osteosarcoma
• ovarian cancer (OC) 9

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab plus pomalidomide and dexamethasone

• versus all
• vs Immunosuppressant
• vs pomalidomide based treatment
• vs pomalidomide and dexamethasone

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  multiple myeloma - 2nd line (L2);